Reduced Incidence of Acute Graft Versus Host Disease (GVHD) and Transplant-Related Mortality (TRM) with the Addition of Short-Course Mini-Dose Methotrexate (MTX) to Cyclosporine (CSA) as GVHD Prophylaxis Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

@inproceedings{Srinivasan2007ReducedIO,
  title={Reduced Incidence of Acute Graft Versus Host Disease (GVHD) and Transplant-Related Mortality (TRM) with the Addition of Short-Course Mini-Dose Methotrexate (MTX) to Cyclosporine (CSA) as GVHD Prophylaxis Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).},
  author={Ramaprasad Srinivasan and Haley K. Hedlin and Rose Goodwin and Aleah L. Smith and Catalina Sierra Ramos and Lisa Fineberg Cook and Charles D. Bolan and Hisayuki Yokoyama and Sunil K. Srivastava and Jennifer M. Karpovich and Teresa Donohue and John Stephen Barrett and Nancy L. Geller and Richard W. Childs},
  year={2007}
}
Acute GVHD is a major cause of morbidity and mortality following NST. A high incidence of aGVHD occurs when CSA alone is used as prophylaxis. We investigated the effect of combining either mycophenolate mofetil (MMF) or an abbreviated course of low dose MTX with CSA on the incidence and severity of aGVHD. Between 11/97 and 07/07, 230 consecutive patients (pts) (solid tumors n=127, hematologic malignancies n=57, non-malignant hematologic disorders n=46) underwent conditioning with fludarabine… CONTINUE READING